More Than Just a Testing Lab, Nucro-Technics Is Your Contract Testing Laboratory R&D Partner
Nucro-Technics is Canada’s largest privately-owned Contract Research / Contract Support Organization, routinely completing projects for 40 of the 50 biggest pharmaceutical, biotech, and medical device companies worldwide. With a client base that spans from virtual companies at the Investigation New Drug-enabling stage to multinational conglomerates requiring finished product release testing, Nucro-Technics supports all phases of pharmaceutical development. Accredited by Health Canada, the FDA, the Standards Council of Canada, and ISO-certified to the 9001: 2015 standard, Nucro-Technics has decades of experience across many therapeutic indications.
COMMON SERVICES OFFERED BY APPLICATION
GMP Finished Product Testing
GLP IND-Enabling Studies
Marijuana Testing
Clinical Trial Support
Proteomics
Stability Studies
News / Updates
Frontage Acquires Nucro-Technics Inc. and Nucro-Technics Holdings, Inc.
August 15, 2023: Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc. Nucro-Technics is a pharmaceutical contract research organization that conducts [...]
Nucro-Technics at the 2023 Society of Toxicology 62nd Annual Meeting and ToxExpo
As with every year in March, five thousand attendees throughout the pharmaceutical and biotech industry converge on a city in the United States for the Society of Toxicology ToxExpo Meeting / Conference. These attendees [...]
Pesticide Residue Testing with USP <561>
In order to meet the safety standards enforced by regulatory authorities, food commodities and botanicals are required to undergo pesticide residue testing. The tests described in the U.S. Pharmacopoeia <561> “Articles of Botanical Origin” [...]
Nitrosamine Impurities Testing With the Updated FDA Guidance
Nitrosamine impurities have recently become a very important topic in the world of pharmaceuticals. Ever since unacceptable levels of this probable carcinogen were detected in common drugs (including angiotension II receptor blockers, Zantac, metformin), [...]